Pivotal Therapeutics Inc (PVTTF: OTCQX International) |

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pivotal Therapeutics Inc (PVTTF: OTCQX International) | Pivotal Therapeutics Announces First Quarter Financial Results Pivotal Therapeutics Announces First Quarter Financial Results

Pivotal Therapeutics Announces First Quarter Financial Results

Canada NewsWire

WOODBRIDGE, ON , May 30, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014 .  All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

Financial Results

For the three months ended March 31, 2014 , the Company reported a loss of $1,613,667 , or $0.02 per common share.  This included $508,952 in non-cash expenses related to the awarding of stock options in the period.  In last year's first quarter, the loss was  $783,436, or $0.01 per common share.

The Company ended the 2014 first quarter in a significantly improved financial position.  At March 31, 2014 , Pivotal's cash totaled $4,617,305 compared with $487,199 at December 31, 2013 .

"Going into 2014, we mapped out an aggressive agenda which included the expansion of our sales, marketing, reimbursement support and R&D activities to help increase our commercial footprint and reach a much larger doctor and patient population," commented Mr. Eugene Bortoluzzi , Pivotal's CEO and CFO. "However, until late in the first quarter, a lack of available financial resources delayed our ability to execute those plans.  While still somewhat constrained in that respect, we are now in a position to start implementing our growth strategy.  We look forward to updating our stakeholders as we progress throughout the rest of the year." 

The audited consolidated financial statements, accompanying notes thereto and Management's Discussion and Analysis for the three months ended March 31, 2014 , will be accessible on SEDAR www.sedar.com , CSE www.cnsx.ca under the symbol "PVO" and OTCQX www.otcqx.com under the symbol "PVTTF".

Operational Highlights Since December 2013 :

  • January 29, 2014 - The Company announced a Notice of Allowance for the patent entitled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics";

  • March 4, 2014 - The Company closed the debt financing and receives over CDN $7.7 million to further Vascazen ® commercialization;

  • March 14, 2014 and April 8, 2014 - The Company awarded stock options that were granted previously to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012 and 2013 and were awaiting the conclusion of the aforementioned debt financing;

  • April 23, 2014 – The Company announces the resignation of two directors, Dr. John P. Nicholson Jr. and Mr. James Connolly , both nominees of Crossover Healthcare Fund, LLC.;

  • May 1 and May 6 2014 – the Company announced the presentation of two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario, Canada , May 1-3, 2014 ;

  • May 7, 2014 – the Company announced the issuance of U.S. Patent 8,715,648 for its Unique 6:1 EPA:DHA formulation;

  • May 13, 2014 – the Company engaged Brandkarma LLC., an award winning, US-based, healthcare marketing and brand specialist with global expertise to support the Company's commercialization strategy for Vascazen ® ;

  • May 14, 2014 – the Company announced changes to its Board designed to increase its independence and enhance Pivotal's corporate governance at this stage of the Company's development.


 Pivotalʼs Goals for 2014:

  • Drive top-line revenues;
  • Develop a point-of-care diagnostic test to measure Omega-3 deficiency (OM3D);
  • Advance commercialization of Vascazen ® in the U.S. and internationally;
  • Advance commercialization of OMAZEN ® in Canada ;
  • Expansion of the sales & marketing initiatives;
  • Initiation of new clinical trials;
  • Publication of scientific data;
  • Expansion of intellectual property portfolio;
  • Investigation of international licensing opportunities;
  • Expansion of product offerings;
  • Investment community presentations to increase awareness;
  • Presentations and attendance at scientific meetings.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN ® is a prescription only Medical Food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN ® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN ® is a patented product available for sale and distribution in Canada .

About VASCAZEN ®

VASCAZEN ® is currently available in the U.S. as a prescription only Medical Food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN ® is a > 90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN ® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile.   VASCAZEN ® 's results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.

Disclosure Notice
The information contained in this document is as of May 30, 2014 . This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 246

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 53

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 60

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 125

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Sable Offshore Investors on Class Action

Updated Category News Views 261

Important Update for Sable Offshore Investors Sable Offshore Corp. (SOC), a prominent player in the oil transportation industry, is currently entangled in legal proceedings that have implications for its investors. If you've invested in SOC and suffered losses exceeding $100,000, there are critical updates you need to be aware of. Details on the Class Action Lawsuit A...

Continue Reading
Polestar Automotive Faces Lawsuit Over Financial Discrepancies

Updated Category News Views 353

Overview of the Legal Situation Concerning Polestar Automotive Recent events have brought attention to Polestar Automotive Holding UK PLC (NASDAQ: PSNY), a company known for its electric vehicles. A securities class action lawsuit has emerged, filed in the United States District Court for the District of New Jersey. This legal action is essential for individuals who...

Continue Reading
Quest Diagnostics' Q3 2024 Performance Boosts Annual Outlook

Updated Category News Views 257

Quest Diagnostics Reports Impressive Q3 2024 Financial Results Quest Diagnostics Incorporated (NYSE: DGX), a top provider of diagnostic information services, has shared its encouraging financial performance for the third quarter ended September 30, 2024. The company saw a notable increase in revenues, reaching $2.49 billion, representing an 8.5% rise compared to the...

Continue Reading
Castle Biosciences Receives NY Health Approval for TissueCypher

Updated Category News Views 118

Castle Biosciences Gains Approval for Revolutionary Test Castle Biosciences, Inc. (NASDAQ: CSTL), based in Friendswood, Texas, is charting a transformative course in healthcare with its recent approval from the New York State Department of Health for its TissueCypher Barrett’s Esophagus test. This achievement marks a significant milestone as TissueCypher stands out as...

Continue Reading
Oryzon Genomics to Conduct Insightful Virtual KOL Event

Updated Category News Views 147

Oryzon Genomics to Host Virtual KOL Event Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), renowned for its innovations in the field of epigenetics, has announced an engaging virtual KOL event aimed at addressing the complexities of Borderline Personality Disorder (BPD). This event, scheduled for a Wednesday at 12:00 pm ET, will be expertly moderated by Dr. Michael...

Continue Reading